Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2003

View Archived Issues

Omiloxetine characterized as SSRI with potential in depression

Improvement associated with AC-2592 in advanced heart failure patients

Beneficial effects of NM-702 in intermittent claudication

Similar efficacy of CVT-3146 and adenosine in detecting myocardial ischemia

Two series of complement C5a receptor modulators patented by Neurogen

Merck claims novel cannabinoid CB1 modulators with utility as antiobesity agents

New pyridoxal-based HIV integrase inhibitors covered by Pharmacor patent

AstraZeneca researchers design novel GSK-3 inhibitors for AD therapy

Japanese team identifies compounds with leukocyte-enhancing and DPP-IV-inhibitory activity

Novel HIV protease inhibitors prepared and tested at Pharmacor

Lilly scientists discover new ERbeta agonists for use in prostate cancer

Rho kinase inhibitors discovered at Sumitomo

Assessment of the benefits of enfuvirtide in HIV-infected patients

Good efficacy and safety profile of ocinaplon in GAD

Efficacy and safety of NO-aspirin demonstrated in mice and in healthy subjects

Positive preliminary results for AVR-118 in cachexia

Exenatide meets glucose control endpoint in second of three pivotal trials

Arpida and Polyphor to discover new antibacterial and antifungal compounds

Six-month Eligard product completes phase III trial

Enrollment begins in ASSENT 4 PCI trial

EpiTan plans IND filing for Melanotan

Immunomedics negotiating return of epratuzumab rights from Amgen

Treatment under way in ML's phase II prostate cancer study

No morning residual effects after middle-of-night administration of indiplon

Plexxikon supplies novel kinase inhibitor to Genentech

Completion of first dose level in Oxycyte phase I study

Grant supports development of Resmycin

Cognition-enhancing effects demonstrated for selective histamine H3 receptor antagonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.